IQVIA Holdings Inc.
IQV Healthcare Diagnostics & Research
IQVIA Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $16.3 billion, up 5.87% from fiscal 2024. In the quarter to June 2026, revenue grew 8.74%, EPS was flat, free cash flow grew 23.3% and total debt rose 3.29%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.
Follow IQV
IQVIA Holdings Inc. (IQV) Net income
IQVIA Holdings Inc.'s net income for fiscal 2025 was $1.4B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $1.4B. Over the past ten years it has ranged from $87.0M (fiscal 2016) to $1.4B (fiscal 2024); the current reading is higher than 91% of that period. IQVIA Holdings Inc. ranks 4th of 52 Diagnostics & Research companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $1.4B | (0.87%) |
| FY2024 | $1.4B | 1.10% |
| FY2023 | $1.4B | 24.47% |
| FY2022 | $1.1B | 12.36% |
| FY2021 | $971.0M | 215.26% |
| FY2020 | $308.0M | 35.68% |
| FY2019 | $227.0M | (20.07%) |
| FY2018 | $284.0M | (78.09%) |
| FY2017 | $1.3B | 1,389.66% |
| FY2016 | $87.0M | (77.58%) |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $258.0M | (6.18%) |
| Mar 2026 | $275.0M | (46.50%) |
| Dec 2025 | $514.0M | 54.82% |
| Sep 2025 | $332.0M | 24.81% |
| 42 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| A Agilent Technologies, Inc. compare | $1.4B |
| IQV IQVIA Holdings Inc. | $1.4B |
| IDXX IDEXX Laboratories, Inc. compare | $1.1B |
| DGX Quest Diagnostics Incorporated compare | $1.1B |
| LH Labcorp Holdings Inc. compare | $1.0B |
| MTD Mettler-Toledo International, Inc. compare | $905.6M |
| ILMN Illumina, Inc. compare | $824.0M |
| WAT Waters Corporation compare | $166.6M |
| NTRA Natera, Inc. compare | −$192.3M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on IQV
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement